Thinking and memory in adults with lymphoma receiving CAR-T cell therapy
Follows thinking and memory in adults with B-cell lymphoma treated with CAR-T.
Plain-language title generated from the registry record
Registry title: Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy
Key facts
- Where
- Alessandria, Ancona, Brescia, Palermo, Reggio Calabria, Roma, Taranto, and Udine, ItalySee the 8 sites
Where in Italy
- SCDU Ematologia - AOU SS. Antonio e Biagio e Cesare Arrigo di AlessandriaAlessandria, ItalyNo longer taking part
- Clinica di Ematologia, AOU Ospedali RiunitiAncona, ItalyNo longer taking part
- USD-TMO Adulti - ASST Spedali Civili di BresciaBrescia, ItalyNo longer taking part
- Divisione di Ematologia - A.O. Ospedali Riuniti Villa Sofia-CervelloPalermo, ItalyNo longer taking part
- Ematologia - Grande Ospedale Metropolitano Bianchi Melacrino MorelliReggio Calabria, ItalyNo longer taking part
- Ematologia - Università Cattolica S. CuoreRoma, ItalyNo longer taking part
- SC Ematologia - Ospedale "S.G. Moscati"Taranto, ItalyNo longer taking part
- SOC Clinica Ematologica - Azienda Sanitaria Universitaria Friuli Centrale (ASU FC)Udine, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione Italiana Linfomi - ETS
- Trial code
- NCT07463781
- Record updated
- 13 March 2026
- Original description
This is an observational, multicenter, prospective cohort study including patients treated with CAR-T in Italian centers. Patients eligible for enrollment in the study will be consecutively included in Italian FIL centers. A longitudinal survey will be carried out by collecting patients' data before starting CAR-T (T0) and after 6 (T1), 12 (T2) and 24 (T3) months after CAR-T infusion.Read full original descriptionShow less
Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy: a Multicenter Observational Prospective Study
This is an observational, multicenter, prospective cohort study including patients treated with CAR-T in Italian centers. Patients eligible for enrollment in the study will be consecutively included in Italian FIL centers. A longitudinal survey will be carried out by collecting patients' data before starting CAR-T (T0) and after 6 (T1), 12 (T2) and 24 (T3) months after CAR-T infusion.
Inclusion: Patients with previous diagnosis of Diffuse Large B Cell Lymphoma or High- Grade B Cell Lymphoma (DLBCL/HGBL), arising de novo or transformed from a previous indolent histotype (transformed Follicular Lymphoma or transformed Marginal Zone Lymphoma), Primary Mediastinal B Cell Lymphoma (PMBCL); Patients undergoing CD19-targeted CAR-T cell salvage therapy for relapsed/refractory disease according to AIFA inclusion criteria; Age over 18-years-old at the time of lymphoma diagnosis.
Exclusion: Patients that received brain/neuroaxis radiotherapy; Patients with CNS disease localization; Pre-existing severe psychiatric or neurologic comorbidities influencing neurocognitive assessment; Patient with histological diagnosis of mantle cell lymphoma (MCL) or acute lymphoblastic leukemia (ALL).